1. < Home

Cabotegravir

HIV DNA Levels in Persons Who Acquired HIV in the Setting of Long-Acting Cabotegravir for HIV Prevention: Analysis of Cases from HPTN 083 and 084

Fogel JM, Persaud D, Piwowar-Manning E, Richardson P, Szewczyk J, Marzinke MA, Wang Z, Guo X, McCauley M, Farrior J, Tran HV, Ungsedhapand C, Mathew[...]

By sjmartinez • October 29, 2024
Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP

Han K, Patel P, McCallister S, Rinehart AR, Gandhi Y, Spreen W, Landovitz RJ, Delany-Moretlwe S, Marzinke MA, McKeon T, Budnik P, van Wyk J,[...]

By sjmartinez • May 7, 2024
Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083

Marzinke MA, Fogel JM, Wang Z, Piwowar-Manning E, Kofron R, Moser A, Bhandari P, Gollings R, Bushman LR, Weng L, Halvas EK, Mellors J, Anderson[...]

By sjmartinez • March 31, 2023
Estimating the impact of HIV PrEP regimens containing long-acting injectable cabotegravir or daily oral tenofovir disoproxil fumarate/emtricitabine among men who have sex with men in the United States: a mathematical modelling study for HPTN 083

Mitchell KM, Boily MC, Hanscom B, Moore M, Todd J, Paz-Bailey G, Wejnert C, Liu A, Donnell DJ, Grinsztejn B, Landovitz RJ, Dimitrov DT. Estimating[...]

By sjmartinez • February 28, 2023
Development and validation of a liquid chromatographic-tandem mass spectrometric assay for the quantification of cabotegravir and rilpivirine from dried blood spots

Weld ED, Parsons TL, Gollings R, McCauley M, Grinsztejn B, Landovitz RJ, Marzinke MA. Development and validation of a liquid chromatographic-tandem mass spectrometric assay for[...]

By sjmartinez • February 27, 2023